keyword
https://read.qxmd.com/read/38633113/hairy-cell-leukemia-with-plasmacytoid-morphology
#1
JOURNAL ARTICLE
Siba El Hussein, Dennis P O'Malley
No abstract text is available yet for this article.
April 2024: EJHaem
https://read.qxmd.com/read/38626745/prognostic-implications-of-circulating-plasma-cell-percentage-in-multiple-myeloma-and-primary-plasma-cell-leukemia-defined-by-new-criteria
#2
JOURNAL ARTICLE
Xianghong Jin, Xianyong Jiang, Hui Li, Kaini Shen, Shuangjiao Liu, Miao Chen, Chen Yang, Bing Han, Junling Zhuang
INTRODUCTION: The definition of primary plasma cell leukemia (pPCL) has been revised from ≥20% to ≥5% circulating plasma cells (CPC). However, the precise prognosis associated with CPC remains controversial. This study aimed to investigate prognostic biomarkers for myeloma patients based on CPC presence. METHODS: A comprehensive analysis was conducted on 309 consecutive patients diagnosed with either multiple myeloma or pPCL, utilizing peripheral blood smears stained with Wright-Giemsa...
April 16, 2024: Acta Haematologica
https://read.qxmd.com/read/38613900/a-novel-fluorescent-probe-based-imprinted-polymer-coated-magnetite-for-the-detection-of-imatinib-leukemia-anti-cancer-drug-traces-in-human-plasma-samples
#3
JOURNAL ARTICLE
Heba M Hashem, Eslam A Ghaith, Amira Eladl, Samira M Abozeid, A B Abdallah
Myeloid leukemia is a chronic cancer, which associated with abnormal BCR-ABL tyrosine kinase activity. Imatinib (IMB) acts as a tyrosine kinase inhibitor and averts tumor growth in cancer cells by controlling cell division, so it is urgent to develop an effective assay to detect and monitor its IMB concentration. Therefore, an innovative fluorescent biomimetic sensor is a promising sensing material that constructed for the efficient recognition of IMB and displays excellent selectivity and sensitivity stemming from molecularly imprinted polymer@Fe3 O4 (MIP@Fe3 O4 )...
April 10, 2024: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
https://read.qxmd.com/read/38600883/the-mechanism-of-action-pharmacological-characteristics-and-clinical-utility-of-the-amyloid-depleter-birtamimab-for-the-potential-treatment-of-al-amyloidosis
#4
REVIEW
Giovanni Palladini, Michaela Liedtke, Wagner Zago, Phil Dolan, Gene G Kinney, Morie A Gertz
Amyloid light chain (AL) amyloidosis is a progressive plasma cell disorder caused by amyloid deposition resulting in organ damage and failure. Current standard-of-care treatments target clonal plasma cells, the source of misfolded light chains (amyloid precursors), yet only half of patients with advanced disease survive ≥6 months. The amyloid depleter birtamimab is an investigational humanized monoclonal antibody that binds misfolded κ and λ light chains with high specificity and was designed to neutralize soluble toxic light chain aggregates and promote phagocytic clearance of deposited amyloid...
April 11, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38600316/combination-p53-activation-and-bcl-x-l-bcl-2-inhibition-as-a-therapeutic-strategy-in-high-risk-and-relapsed-acute-lymphoblastic-leukemia
#5
JOURNAL ARTICLE
Hayden L Bell, Helen J Blair, Samantha J Jepson Gosling, Martin Galler, Daniel Astley, Anthony V Moorman, Olaf Heidenreich, Gareth J Veal, Frederik W van Delft, John Lunec, Julie A E Irving
Due to the rarity of TP53 mutations in acute lymphoblastic leukemia (ALL), p53 re-activation by antagonism of the p53-MDM2 interaction represents a potential therapeutic strategy for the majority of ALL. Here, we demonstrate the potent antileukemic activity of the MDM2 antagonist idasanutlin in high-risk and relapsed ex vivo coculture models of TP53 wildtype ALL (n = 40). Insufficient clinical responses to monotherapy MDM2 inhibitors in other cancers prompted us to explore optimal drugs for combination therapy...
April 10, 2024: Leukemia
https://read.qxmd.com/read/38581379/gammopathic-dermopathy-characterization-of-cutaneous-mgus
#6
JOURNAL ARTICLE
Emily R Gordon, Caroline Chen, Megan H Trager, Oluwaseyi Adeuyan, Brigit A Lapolla, Lauren M Fahmy, Celine M Schreidah, David A Wetter, Larisa J Geskin
Monoclonal Gammopathy of Undetermined Significance (MGUS) is a clonal plasma cell disorder that is considered preneoplastic, asymptomatic, and only requiring observation. However, MGUS may result in cutaneous complications, which are poorly understood, causing treatment delays and patient suffering. We present 30 patients with cutaneous findings associated with MGUS, characterizing clinical presentations, isoforms, treatments, and outcomes. These included: MGUS-associated 'rashes' (pruritic eczematous rashes), reactive and mucin-depositional conditions (pyoderma gangrenosum, scleromyxedema), M-protein-related deposition disorders (POEMS syndrome, Waldenstrom macroglobulinemia), and cutaneous lymphomas...
April 6, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38579288/il-18-secreting-multi-antigen-targeting-car-t-cells-eliminate-antigen-low-myeloma-in-an-immunocompetent-mouse-model
#7
JOURNAL ARTICLE
Brandon D Ng, Adhithi Rajagopalan, Anastasia I Kousa, Jacob S Fischman, Sophia Chen, Alyssa Rae Massa, Harold K Elias, Dylan Manuele, Michael Galiano, Andri L Lemarquis, Alexander P Boardman, Susan DeWolf, Jonah Addison Pierce, Bjarne Bogen, Scott E James, Marcel R M van den Brink
Multiple myeloma is a plasma cell malignancy that is currently incurable with conventional therapies. Following the success of CD19-targeted chimeric antigen receptor (CAR) T-cells in leukemia and lymphoma, CAR T-cells targeting B-cell maturation antigen (BCMA) more recently demonstrated impressive activity in relapsed and refractory myeloma patients. However, BCMA-directed therapy can fail due to low expression of BCMA on myeloma cells, suggesting that novel approaches to better address antigen-low disease may improve patient outcomes...
April 5, 2024: Blood
https://read.qxmd.com/read/38574862/biomarkers-of-bleeding-and-venous-thromboembolism-in-patients-with-acute-leukemia
#8
JOURNAL ARTICLE
Yohei Hisada, Sierra J Archibald, Karan Bansal, Yanjun Chen, Chen Dai, Sindhu Dwarampudi, Nora Balas, Lindsey Hageman, Nigel S Key, Smita Bhatia, Ravi Bhatia, Nigel Mackman, Radhika Gangaraju
BACKGROUND: Coagulopathy and associated bleeding and deep vein thrombosis (DVT) are major causes of morbidity and mortality in patients with acute leukemia. The underlying mechanisms of these complications have not been fully elucidated. OBJECTIVES: To evaluate the associations between biomarker levels and bleeding and DVT in acute leukemia patients. PATIENTS/METHOD: We examined plasma levels of activators, inhibitors and biomarkers of the coagulation and fibrinolytic pathways in patients ≥18 years with newly diagnosed acute leukemia compared to normal controls...
April 2, 2024: Journal of Thrombosis and Haemostasis: JTH
https://read.qxmd.com/read/38561877/gaucher-disease-a-first-reported-adult-case-in-indonesia
#9
JOURNAL ARTICLE
Ardhi Rahman Ahani, Cosphiadi Irawan, Agnes Stephanie Harahap, Klara Yuliarti, Maria Francisca Ham, Faramitha Nur Izzaty, Damayanti Rusli Sjarif
A 44-year-old female presented with a distended abdomen and fatigue. On physical examination, prominent splenomegaly was found. The laboratory investigations revealed pancytopenia and decreased albumin-globulin ratio. The abdominal ultrasonography revealed splenomegaly, cholelithiasis, and cystitis, and the bone survey showed osteopenia. Differential diagnoses included leukemia, multiple myeloma, and myelofibrosis therefore bone marrow puncture was performed. However, histopathologic examination found Gaucher-like cells in the bone marrow aspiration...
January 2024: Acta Medica Indonesiana
https://read.qxmd.com/read/38559181/interpreting-single-cell-messages-in-normal-and-aberrant-hematopoiesis-with-the-cell-marker-accordion
#10
Emma Busarello, Giulia Biancon, Fabio Lauria, Zuhairia Ibnat, Christian Ramirez, Gabriele Tomè, Kristin R Aass, Jennifer VanOudenhove, Therese Standal, Gabriella Viero, Stephanie Halene, Toma Tebaldi
UNLABELLED: Single-cell technologies offer a unique opportunity to explore cellular heterogeneity in hematopoiesis, reveal malignant hematopoietic cells with clinically significant features and measure gene signatures linked to pathological pathways. However, reliable identification of cell types is a crucial bottleneck in single-cell analysis. Available databases contain dissimilar nomenclature and non-concurrent marker sets, leading to inconsistent annotations and poor interpretability...
March 12, 2024: bioRxiv
https://read.qxmd.com/read/38557364/express-a-new-therapeutic-perspective-erastin-inhibits-tumor-progression-by-driving-ferroptosis-in-myelodysplastic-syndromes
#11
JOURNAL ARTICLE
Junlan Ma, Wei Zhang, Jiaojiao Li, Rui Zhang, Yan Zhai, Rong Fu
Ferroptosis is a recently identified and evolutionarily conserved form of programmed cell death. This process is initiated by an imbalance in iron metabolism, leading to an overload of ferrous ions. These ions promote lipid peroxidation in the cell membrane through the Fenton reaction. As the cell's antioxidant defenses become overwhelmed, a fatal build-up of reactive oxygen species (ROS) occurs, resulting in the rupture of the plasma membrane. Ferroptosis is implicated in conditions such as ischemia-reperfusion injuries and a range of cancers...
April 1, 2024: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://read.qxmd.com/read/38557299/successful-treatment-with-bortezomib-thalidomide-and-dexamethasone-in-plasma-cell-myeloma-post-bone-marrow-transplant
#12
JOURNAL ARTICLE
Yaqing Cao, Jingjing Shang, Yingying Zhai, Qingyuan Wang, Lingzhi Yan, Xiaolan Shi, Jing Wang, Ying Yao, Huifen Zhou, Aining Sun, Miao Miao, Chengcheng Fu, Song Jin
No abstract text is available yet for this article.
April 1, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38557174/deletion-of-the-tmem30a-gene-enables-leukemic-cell-evasion-of-nk-cell-cytotoxicity
#13
JOURNAL ARTICLE
Linnea Kristenson, Chiara Badami, Angelica Ljungberg, Erna Islamagic, Yarong Tian, Guojiang Xie, Brwa Ali Hussein, Silvia Pesce, Ka-Wei Tang, Fredrik B Thorén
Natural killer (NK) cell immunotherapy has gained attention as a promising strategy for treatment of various malignancies. In this study, we used a genome-wide CRISPR screen to identify genes that provide protection or susceptibility to NK cell cytotoxicity. The screen confirmed the role of several genes in NK cell regulation, such as genes involved in interferon-γ signaling and antigen presentation, as well as genes encoding the NK cell receptor ligands B7-H6 and CD58. Notably, the gene TMEM30A , encoding CDC50A-beta-subunit of the flippase shuttling phospholipids in the plasma membrane, emerged as crucial for NK cell killing...
April 9, 2024: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/38542393/landscape-of-flt3-variations-associated-with-structural-and-functional-impact-on-acute-myeloid-leukemia-a-computational-study
#14
JOURNAL ARTICLE
Zeenat Mirza, Dalal A Al-Saedi, Nofe Alganmi, Sajjad Karim
Acute myeloid leukemia (AML) is hallmarked by the clonal proliferation of myeloid blasts. Mutations that result in the constitutive activation of the fms-like tyrosine kinase 3 ( FLT3 ) gene, coding for a class III receptor tyrosine kinase, are significantly associated with this heterogeneous hematologic malignancy. The fms-related tyrosine kinase 3 ligand binds to the extracellular domain of the FLT3 receptor, inducing homodimer formation in the plasma membrane, leading to autophosphorylation and activation of apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow...
March 18, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38537358/detection-of-terminal-deoxynucleotidyl-transferase-activity-based-on-self-mediated-nucleic-acid-elongation-and-elemental-labeling-inductively-coupled-plasma-mass-spectrometry
#15
JOURNAL ARTICLE
Yuwei Liu, Beibei Chen, Man He, Bin Hu
Terminal deoxynucleotidyl transferase (TdT), a specialized DNA polymerase, is recognized as a promising biomarker for acute leukemia. Herein, taking the advantage of the self-mediated strand elongation property of TdT, a simple and sensitive method for TdT activity assay was developed based on gold nanoparticles (AuNPs) labeling inductively coupled plasma mass spectrometry (ICP-MS). In the presence of TdT, the primer DNA on magnetic beads is elongated with an adenine-rich single stranded long chain that can label poly-thymine modified AuNPs...
March 22, 2024: Talanta
https://read.qxmd.com/read/38535786/bee-venom-composition-and-anticancer-properties
#16
REVIEW
Goran Gajski, Elina Leonova, Nikolajs Sjakste
Among the various natural compounds used in alternative and Oriental medicine, toxins isolated from different organisms have had their application for many years, and Apis mellifera venom has been studied the most extensively. Numerous studies dealing with the positive assets of bee venom (BV) indicated its beneficial properties. The usage of bee products to prevent the occurrence of diseases and for their treatment is often referred to as apitherapy and is based mainly on the experience of the traditional system of medical practice in diverse ethnic communities...
February 29, 2024: Toxins
https://read.qxmd.com/read/38531816/simultaneous-determination-of-ibrutinib-dihydroxydiol-ibrutinib-and-zanubrutinib-in-human-plasma-by-liquid-chromatography-mass-spectrometry-mass-spectrometry
#17
JOURNAL ARTICLE
Yu-Jiao Guo, Tian-Tian Du, Yan-Ling Yang, Yang Zhao, Xiang-Long Chen, Hong Ma, Lu-Ning Sun, Yong-Qing Wang
BACKGROUND: Ibrutinib and zanubrutinib are Bruton tyrosine kinase inhibitors used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Dihydroxydiol ibrutinib (DHI) is an active metabolite of the drug. A liquid chromatography-tandem mass spectrometry method was developed to detect ibrutinib, DHI, and zanubrutinib in human plasma. METHODS: The method involved a protein precipitation step, followed by chromatographic separation using a gradient of 10 mM ammonium acetate (containing 0...
March 21, 2024: Therapeutic Drug Monitoring
https://read.qxmd.com/read/38511268/steroid-free-combination-of-5-azacytidine-and-venetoclax-for-the-treatment-of-multiple-myeloma
#18
JOURNAL ARTICLE
Lyndsey Flanagan, Aisling Coughlan, Nicola Cosgrove, Andrew Roe, Yu Wang, Stephanie Gilmore, Izabela Drozdz, Claire Comerford, Jeremy Ryan, Emma Minihane, Salma Parvin, Michael O'Dwyer, John Quinn, Philip Murphy, Simon Furney, Siobhan Glavey, Tríona Ní Chonghaile
Multiple Myeloma (MM) is an incurable plasma cell malignancy, that despite an unprecedented increase in overall survival, lacks truly risk-adapted or targeted treatments. A proportion of patients with MM depend on BCL-2 for survival and recently the BCL-2 antagonist venetoclax has shown clinical efficacy and safety in t(11;14) and BCL-2 overexpressing MM. However, only a small proportion of MM patients rely on BCL-2 (~20%), there is a need to broaden the patient population outside of t(11;14) that can be treated with venetoclax...
March 21, 2024: Haematologica
https://read.qxmd.com/read/38501758/lymphoplasmacytic-lymphoma-and-multiple-myeloma-coexisting-in-the-same-patient-a-case-series-and-literature-review
#19
JOURNAL ARTICLE
Gilad Itchaki, Osnat Jarhovsky, Jorge J Castillo, Hamza Hassan, Moshe L Gatt, Merav Leiba, Pia Raanani, Morie A Gertz, Iuliana Vaxman
The simultaneous occurrence of Waldenström macroglobulinemia and multiple myeloma in the same patient has been published as case reports. Patients with Waldenström macroglobulinemia often have a small clone of plasma cells. However, the concurrent occurrence of symptomatic myeloma with lytic bone lesions is rare. The diagnosis of this 'hybrid' entity is challenging, and there are no standard therapies. We present six patients from five centers (three in Israel and two in the United States). We describe these patients' unique clinical course and treatment approaches...
March 19, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38493476/ankrd26-is-a-retinoic-acid-responsive-plasma-membrane-binding-and-shaping-protein-critical-for-proper-cell-differentiation
#20
JOURNAL ARTICLE
Anna Sofie Englisch, Sarah Ann Hofbrucker-MacKenzie, Maryam Izadi-Seitz, Michael Manfred Kessels, Britta Qualmann
Morphogens are important triggers for differentiation processes. Yet, downstream effectors that organize cell shape changes in response to morphogenic cues, such as retinoic acid, largely remain elusive. Additionally, derailed plasma membrane-derived signaling often is associated with cancer. We identify Ankrd26 as a critical player in cellular differentiation and as plasma membrane-localized protein able to self-associate and form clusters at the plasma membrane in response to retinoic acid. We show that Ankrd26 uses an N-terminal amphipathic structure for membrane binding and bending...
March 15, 2024: Cell Reports
keyword
keyword
27020
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.